# PEDRA Technology

> PEDRA Technology is a Singapore-based medical device company that built the PEDRA Xauron Perfusion System, the first device to deliver real-time, quantitative measurement of deep-tissue blood perfusion in the foot during vascular procedures. Aimed at physicians treating peripheral arterial disease (PAD) and critical limb threatening ischemia (CLTI), the laser-based, non-invasive system gives interventionalists objective feedback in the angio suite - where they have historically relied on subjective interpretation of X-ray images. The company raised a $4.7M Series A in 2020 and won FDA Breakthrough Device Designation in 2021.

- **Founded:** 2014
- **Headquarters:** Singapore
- **Founders:** Kareen Looi (CEO & Founder)
- **Team size:** Small (roughly 2-10; listed as ~2 employees in Apollo data)
- **Products:** PEDRA Xauron Perfusion System
- **Notable:** Developed what the company describes as the first device to achieve real-time, quantitative deep-tissue perfusion monitoring on a quantitative index., Received FDA Breakthrough Device Designation (January 2021) for periprocedural use of the Xauron system in critical limb threatening ischemia., Closed a $4.7M Series A in September 2020 with SEEDS Capital and strategic vascular-device manufacturers.

## Products & services

- **PEDRA Xauron Perfusion System** — A laser-based, non-invasive monitor that provides real-time, quantitative deep-tissue perfusion readings of the foot during vascular procedures. Delivers feedback in under 10 seconds, supports up to 4 channels for multi-angiosome assessment, requires no contrast, and uses radiolucent sensors compatible with angiographic imaging. Portable with battery support.

## Achievements

- Developed what the company describes as the first device to achieve real-time, quantitative deep-tissue perfusion monitoring on a quantitative index.
- Received FDA Breakthrough Device Designation (January 2021) for periprocedural use of the Xauron system in critical limb threatening ischemia.
- Closed a $4.7M Series A in September 2020 with SEEDS Capital and strategic vascular-device manufacturers.
- Built an international clinical advisory board spanning Singapore, the US and Europe.

## Latest updates

- **2020-09** — Closed $4.7M Series A financing led by SEEDS Capital with M&L Healthcare Investments and strategic vascular-device manufacturers.
- **2021-01** — Received FDA Breakthrough Device Designation for the PEDRA Xauron Real-Time Tissue Perfusion System in CLTI.
- **2025-02** — Product materials reference an updated multi-channel Xauron monitoring interface (BPI ratio, multi-sensor foot mapping).

## Links

- Website: https://pedratech.com
- LinkedIn: https://www.linkedin.com/company/pedra-technology
- YouTube: https://www.youtube.com/watch?v=bkQTCmvttOU

---

Profile page: https://yespress.io/pedratech
Published by YesPress — https://yespress.io
Last updated: 2026-07-25